Cardiff Oncology, Inc. (FRA:XE7C)

Germany · Delayed Price · Currency is EUR

1.272

-0.036 (-2.75%)

Last updated: Feb 23, 2026, 8:10 AM CET

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
The Development of Novel Therapies across a Range of Cancers	683.00K	488.00K	386.00K	359.00K	366.00K
The Development of Novel Therapies across a Range of Cancers Growth	39.96%	26.42%	7.52%	-1.91%	49.61%
Total	683.00K	488.00K	386.00K	359.00K	366.00K
Total Growth	39.96%	26.42%	7.52%	-1.91%	49.61%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
United States	683.00K	488.00K	386.00K	359.00K	366.00K
United States Growth	39.96%	26.42%	7.52%	-1.91%	49.61%
Total	683.00K	488.00K	386.00K	359.00K	366.00K
Total Growth	39.96%	26.42%	7.52%	-1.91%	49.61%

Source: S&P Global Market Intelligence.